In this article, we will discuss Ravulizumab-cwvz (Dosage Overview). So, let’s get started.
Ravulizumab-cwvz is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Recommended Vaccination and Prophylaxis
Vaccinate patients for meningococcal disease according to current ACIP guidelines to reduce the risk of serious infection.
Provide 2 weeks of antibacterial drug prophylaxis to patients if Ravulizumab-cwvz must be initiated immediately and vaccines are administered less than 2 weeks before starting Ravulizumab-cwvz therapy.
Healthcare professionals who prescribe Ravulizumab-cwvz must enroll in the ULTOMIRIS REMS
Recommended Weight-Based Dosage Regimen
The recommended dosing regimen for adult patients (≥ 18 years of age) with PNH
consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. Administer the doses based on the patient’s body weight.
Starting 2 weeks after the loading dose administration, begin maintenance doses at a once every 8-week interval. The dosing schedule is allowed to occasionally vary within 7 days of the scheduled infusion day (except for the first maintenance dose of
Ravulizumab-cwvz) but the subsequent dose should be administered according to the original schedule. For patients switching from eculizumab to Ravulizumab-cwvz, administer the loading dose of Ravulizumab-cwvz 2 weeks after the last eculizumab infusion, and then administer maintenance doses once every 8 weeks, starting 2 weeks after loading dose administration.